UTL-5g is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity.

Tebentafusp (IMCgp100) is a protein that specifically targets gp100 and consists of a soluble T-cell receptor functionally fused to an anti-CD3 immune effector Tebentafusp has potential anti-tumor activity, induces the production of inflammatory cytokines and cytolytic proteins, and can be used to study unresectable or metastatic uveal melanoma.

Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis